EMA Lapsed: Somatropin Biopartners (somatropin) — BioPartners GmbH

View source ↗

Summary

The EMA indicates the Somatropin Biopartners product (somatropin) under BioPartners GmbH has lapsed status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Disorders

Drugs mentioned

• Somatropin Biopartners (somatropin)

Snippet

Status: Lapsed. Therapeutic area: Growth. MAH: BioPartners GmbH. Decision date: 13/03/2017